To our knowledge, there is no literature report of targeted testing for the UFM1 founder mutation instead of a panel testing or WES; we have been the first ones to do it in the case of an infant with Hypomyelinating leukodystrophy, and this lead to a faster molecular genetic diagnosis of the patient. The gene discussed is UFM1; the disease is leukodystrophy.